阅读说明：本技术 一种调节血脂血压、提高免疫能力的口服泡腾片及其制备方法 (Oral effervescent tablet for regulating blood fat and blood pressure and improving immunity and preparation method thereof ) 是由 黄春球 梅艳 郭昕 武正才 和丽英 屈安卫 于 2021-08-12 设计创作，主要内容包括：本发明涉及一种调节血脂血压、提高免疫能力的口服泡腾片及其制备方法,属于食品加工领域；该口服泡腾片包括三七须根和/或杜仲、雪莲果和/或葛根,本发明还提供了上述口服泡腾片的制备方法,方法简便,所制成的口服泡腾片具有溶化快、低糖、易消化的优点,兼有提高免疫能力、预防心血管疾病的效果,特别适合中老年人、免疫力低下、高血压高血脂等人群食用。(The invention relates to an oral effervescent tablet for regulating blood fat and blood pressure and improving immunity and a preparation method thereof, belonging to the field of food processing; the invention also provides a preparation method of the oral effervescent tablet, the method is simple, the prepared oral effervescent tablet has the advantages of quick dissolution, low sugar content and easy digestion, has the effects of improving the immunity and preventing cardiovascular diseases, and is particularly suitable for middle-aged and elderly people, people with low immunity, high blood pressure, high blood fat and the like to eat.)

1. An oral effervescent tablet for regulating blood fat and blood pressure and improving immunity, which is characterized in that: comprises the following raw materials: notoginseng radix fibril and/or Eucommiae cortex, yacon and/or radix Puerariae; wherein, the weight portions comprise 300 portions of pseudo-ginseng fibrous root and/or 900 portions of eucommia bark and/or 400 portions of yacon and/or 300 portions of kudzuvine root and 400 portions of kudzuvine root.

2. The effervescent tablet for oral administration for regulating blood fat and blood pressure and improving immunity according to claim 1, wherein the effervescent tablet comprises: the oral effervescent tablet also comprises the following raw materials in parts by weight: 300 parts of pH value regulator 280-3 parts of sweetening agent, 200 parts of filling agent 140-3 parts of lubricating agent.

3. The effervescent tablet for oral administration for regulating blood fat and blood pressure and improving immunity according to claim 2, wherein the effervescent tablet comprises: the pH regulator is one or more of tartaric acid, malic acid, citric acid, sodium bicarbonate, and sodium carbonate.

4. The effervescent tablet for oral administration for regulating blood fat and blood pressure and improving immunity according to claim 2, wherein the effervescent tablet comprises: the sweetener is one or more of sucralose, aspartame and glycyrrhizin.

5. The effervescent tablet for oral administration for regulating blood fat and blood pressure and improving immunity according to claim 2, wherein the effervescent tablet comprises: the filler is one or more of maltodextrin, lactose, soluble starch and mannitol.

6. The effervescent tablet for oral administration for regulating blood fat and blood pressure and improving immunity according to claim 2, wherein the effervescent tablet comprises: the lubricant is one or more of magnesium stearate, talcum powder and silicon dioxide.

7. The method for preparing oral effervescent tablets for regulating blood fat and blood pressure and improving immunity according to any one of claims 1 to 6, which is characterized by comprising the following steps: the method comprises the following steps:

(1) pulverizing raw materials into coarse powder, adding 6-10 times of 70-90% ethanol, extracting under reflux for 2 times with 2 hr each time, filtering, mixing 2 filtrates, concentrating under reduced pressure to obtain extract with relative density of 1.2-1.3(25 deg.C), drying under reduced pressure, pulverizing the dry extract, and sieving with 80 mesh sieve to obtain extract;

(2) adding a filling agent and an alkaline pH regulator into the extract obtained in the step (1), uniformly mixing, granulating by using a soft material prepared from 85% ethanol and a 20-mesh screen, and baking at the temperature of less than or equal to 60 ℃; after the alkali granules are prepared, adding an acidic pH regulator, a filling agent, a sweetening agent and a lubricating agent, uniformly mixing, tabletting and subpackaging to obtain the oral effervescent tablet.

Technical Field

The invention belongs to the field of food processing, and particularly relates to an oral effervescent tablet for regulating blood fat and blood pressure and improving immunity and a preparation method thereof.

Background

Pseudo-ginseng is a very ancient plant, originates from 2 hundred million 5 million old tropical mountainous areas in the third era, is only stored in the mountainous areas in the southwest of China due to special requirements on environmental conditions, is a special species in China, and is mainly distributed in 8 counties of wenshan, inkstone, maguan, western domain, Qibei, Guannan, Funing and Ma chestnut slope in wenshan Zhou of Yunnan province. To date, the yield of wenshansanchi accounts for about 80% of the national yield. In compendium of materia Medica (1765), Ginseng radix tonifies qi first, and Notoginseng radix tonifies blood first, so it is called Ginseng radix Notoginseng, which is the most precious of Chinese herbs. The pseudo-ginseng fibrous root contains various effective components of pseudo-ginseng saponin, flavone, sanchinol, polysaccharide and the like, has the same effect as the main root of pseudo-ginseng, and is the main raw material for preparing famous and precious medicinal food of Yunnan, namely a pseudo-ginseng gas pot chicken. The ginseng fibrous root is used for stewing chicken in folk, so that the blood and qi are best for people. At present, the Chinese medicinal composition is listed as a raw material for food processing in Yunnan province, and can prevent diseases such as coronary heart disease, angina pectoris, arteriosclerosis, hypertension, cerebral thrombosis and the like, increase the immunologic function of a human body, delay senility and build the body after being frequently eaten. The efficacy of the fibrous root of notoginseng is the same as that of the main root of notoginseng. Can dilate blood vessel, lower blood pressure, improve microcirculation, increase blood flow, and prevent and treat ischemia and anoxia of heart and brain tissues; promoting synthesis of protein, ribonucleic acid (RNA) and deoxyribonucleic acid (DNA), and strengthening body constitution; promoting blood cell metabolism, and balancing and regulating blood cells; regulating central nerve bidirectionally, improving mental capacity, and enhancing learning and memory ability; enhancing organism immunity, and resisting tumor; stopping bleeding, promoting blood circulation, and removing blood stasis; protecting liver and resisting inflammation; delaying aging; regulating blood sugar, reducing blood lipid and cholesterol, and inhibiting arteriosclerosis.

Eucommia ulmoides, namely the dried bark of eucommia ulmoides of the family eucommia ulmoides, is a famous and precious Chinese medicinal material for nourishing. It is sweet in taste and warm in nature. Has effects in tonifying liver and kidney, strengthening muscle and bone, regulating Chong and ren meridians, and preventing miscarriage. Can be used for treating lumbago, leg pain, soreness, weakness, and asthenia due to kidney yang deficiency, and symptoms such as hypochondriac instability, and scrotum pruritus due to liver qi deficiency. It is listed as the superior in Shen nong Ben Cao Jing. Contains blood pressure lowering component pinoresinol diglucoside, and also contains coumaric acid, caffeic acid ethyl ester, chlorogenic acid, coniferyl glycoside, gutta alcohol, eucommia ulmoides oliv glycoside, genipin, geniposide, aucubin, ajugaside, kaempferol, quercetin, astragalin, humicoside, rutin, etc. There are also 15 kinds of mineral elements, including trace elements such as Zn, Cu and Fe, and macro elements such as Ca, P, K and Mg.

Kudzu root, name of Chinese traditional medicine. Is dried root of Pueraria lobata Ohwi of Leguminosae, commonly known as Pueraria lobata Ohwi. Collected in autumn and winter, and cut into thick slices or small blocks when fresh; and (5) drying. Sweet, pungent and cool. Has the functions of expelling pathogenic factors from muscles, allaying fever, promoting eruption, promoting the production of body fluid to quench thirst, invigorating yang and stopping diarrhea. It is commonly indicated for exterior syndrome with fever, stiffness and pain of neck and back, measles without adequate eruption, thirst due to fever, diabetes due to yin deficiency, dysentery due to heat-purging and diarrhea due to spleen deficiency.

Yacon is a perennial herb of the family Compositae, and has thin root tuber and skin with much juice and no residue, and the root tuber contains rich water and fructo-oligosaccharide. Yacon has effects of promoting intestinal peristalsis, removing intestinal rubbish, relieving constipation, preventing diarrhea, and improving gastrointestinal function. Improving metabolism level of organism, enhancing immunity and disease resistance, rapidly cleaning enterotoxin, discharging vivotoxin, purifying internal environment, inhibiting harmful substance absorption, and eliminating halitosis caused by vivotoxin.

At present, pseudo-ginseng or eucommia bark is often pressed into tablets for taking, because the pseudo-ginseng and eucommia bark which are raw materials are bitter, the taking compliance of patients is poor, and in addition, the tablets are large, the number of tablets taken at one time is large, and the patients with the old have difficulty in swallowing. Therefore, there is a need to provide a novel and convenient-to-take Chinese medicinal preparation of panax notoginseng or eucommia ulmoides.

Disclosure of Invention

In order to overcome the problems in the background technology, the invention aims to provide an oral effervescent tablet for regulating blood fat and blood pressure and improving immunity.

In order to realize the purpose, the invention is realized by the following technical scheme:

the invention aims to provide an oral effervescent tablet for regulating blood fat and blood pressure and improving immunity, which comprises the following raw materials: notoginseng radix fibril and/or Eucommiae cortex, yacon and/or radix Puerariae; wherein, the weight portions comprise 300 portions of pseudo-ginseng fibrous root and/or 900 portions of eucommia bark and/or 400 portions of yacon and/or 300 portions of kudzuvine root and 400 portions of kudzuvine root.

Further, the oral effervescent tablet also comprises the following raw materials in parts by weight: 300 parts of pH value regulator 280-3 parts of sweetening agent, 200 parts of filling agent 140-3 parts of lubricating agent.

Further preferably, the pH regulator is one or more of tartaric acid, malic acid, citric acid, sodium bicarbonate, and sodium carbonate.

Further preferably, the sweetener is one or more of sucralose, aspartame, glycyrrhizin.

Further preferably, the filler is one or more of maltodextrin, lactose, soluble starch, and mannitol.

Further preferably, the lubricant is one or more of magnesium stearate, talc and silicon dioxide.

The invention also provides a preparation method of the oral effervescent tablet for regulating blood fat and blood pressure and improving immunity, which comprises the following steps:

(1) pulverizing raw materials into coarse powder, adding 6-10 times of 70-90% ethanol, extracting under reflux for 2 times with 2 hr each time, filtering, mixing 2 filtrates, concentrating under reduced pressure to obtain extract with relative density of 1.2-1.3(25 deg.C), drying under reduced pressure, pulverizing the dry extract, and sieving with 80 mesh sieve to obtain extract;

(2) adding a filling agent and an alkaline pH regulator into the extract obtained in the step (1), uniformly mixing, granulating by using a soft material prepared from 85% ethanol and a 20-mesh screen, and baking at the temperature of less than or equal to 60 ℃; after the alkali granules are prepared, adding an acidic pH regulator, a filling agent, a sweetening agent and a lubricating agent, uniformly mixing, tabletting and subpackaging to obtain the oral effervescent tablet.

The invention has the beneficial effects that:

the effervescent tablet provided by the invention has good effects of reducing blood fat and blood sugar and inhibiting over-expression of inflammatory media, and has low adverse reaction. Radix Puerariae or yacon has effects of clearing heat and annealing, and can reduce discomfort of excessive internal heat and sore throat after patients take radix Notoginseng, and radix Puerariae or yacon has effects of enhancing immunity and disease resistance, and can enhance immunity of radix Notoginseng and Eucommiae cortex, protect liver, and prevent cardiovascular disease. Compared with the similar products, the product has the characteristics of convenient carrying, convenient taking, easy digestion and absorption and the like, and is popular with more and more consumers; the oral effervescent tablet has the effects of improving the immunity of the health-care medicinal materials, protecting the liver and preventing cardiovascular diseases, is particularly suitable for middle-aged and elderly people with low immunity and cardiovascular diseases needing health care and prevention, and is also suitable for people with white collar and high blood pressure and high blood fat, and the like with fast life rhythm.

Detailed Description

In order to make the objects, technical solutions and advantages of the present invention more apparent, preferred embodiments of the present invention will be described in detail below to facilitate understanding of the skilled person.

Example 1

(1) Pulverizing Notoginseng radix fibril 300 parts, Eucommiae cortex 900 parts, yacon 300 parts and radix Puerariae 300 parts into coarse powder, adding 6 times of 70% ethanol, extracting under reflux for 2 times, each for 2 hr, filtering, mixing the 2 filtrates, concentrating under reduced pressure to obtain extract with relative density of 1.2(25 deg.C), drying under reduced pressure, pulverizing the dry extract, and sieving with 80 mesh sieve to obtain extract;

(2) adding 100 parts of soluble starch and 140 parts of sodium bicarbonate into the extract obtained in the step (1), mixing uniformly, granulating by using 85% ethanol to prepare a soft material, sieving by using a 20-mesh sieve, and baking at the temperature of less than or equal to 60 ℃. After the alkali granules are prepared, 140 parts of citric acid, 40 parts of soluble starch, 1 part of aspartame and 1 part of magnesium stearate are added and evenly mixed, and tabletting can be carried out;

(3) and (3) subpackaging the tablets obtained in the step (2).

Example 2

(1) Taking 400 parts of pseudo-ginseng fibrous roots, 1200 parts of eucommia ulmoides, 400 parts of yacon and 400 parts of kudzu roots as raw materials, crushing the raw materials into coarse powder, adding 10 times of 90% ethanol, carrying out hot reflux extraction for 2 times, extracting for 2 hours each time, filtering, combining 2 times of extraction filtrates, concentrating under reduced pressure to obtain an extract with the relative density of 1.3(25 ℃), drying under reduced pressure, crushing the dry extract, and sieving with a 80-mesh sieve to obtain an extract;

(2) adding 100 parts of lactose and 150 parts of sodium carbonate into the extract obtained in the step (1), mixing uniformly, granulating by using a soft material prepared by 85% ethanol and a 20-mesh screen, and baking at the temperature of less than or equal to 60 ℃. After the alkali particles are prepared, 150 parts of malic acid, 100 parts of lactose, 3 parts of glycyrrhizin, 1 part of silicon dioxide and 2 parts of talcum powder are added and mixed evenly to be tabletted;

(3) and (3) subpackaging the tablets obtained in the step (2).

Example 3

(1) Pulverizing 333 parts of pseudo-ginseng fibrous roots, 350 parts of yacon and 350 parts of kudzu root into coarse powder, adding 6 times of 85% ethanol, carrying out hot reflux extraction for 2 times, extracting for 2 hours each time, filtering, combining the 2 times of extraction filtrates, concentrating under reduced pressure to obtain an extract with a relative density of 1.3(25 ℃), drying under reduced pressure, pulverizing the dry extract, and sieving with a 80-mesh sieve to obtain an extract;

(2) adding 50 parts of maltodextrin and 140 parts of sodium bicarbonate into the extract obtained in the step (1), uniformly mixing, granulating by using 85% ethanol to prepare a soft material, sieving by using a 20-mesh sieve, and baking at the temperature of less than or equal to 60 ℃. After the alkali granules are prepared, 145 parts of tartaric acid, 100 parts of maltodextrin, 1.1 parts of sucralose and 1 part of magnesium stearate are added and evenly mixed, and tabletting can be carried out;

(3) and (3) subpackaging the tablets obtained in the step (2).

Example 4

(1) Pulverizing 300 parts of Notoginseng radix fibrous root and 350 parts of yacon into coarse powder, adding 10 times of 80% ethanol, extracting under reflux for 2 times, each for 2 hr, filtering, mixing the 2 filtrates, concentrating under reduced pressure to obtain extract with relative density of 1.3(25 deg.C), drying under reduced pressure, pulverizing the dry extract, and sieving with 80 mesh sieve to obtain extract;

(2) adding 180 parts of mannitol and 150 parts of sodium bicarbonate into the extract obtained in the step (1), mixing uniformly, granulating by using 85% ethanol soft material and a 20-mesh screen, and baking at the temperature of less than or equal to 60 ℃. After the alkali granules are prepared, 150 parts of tartaric acid, 2 parts of aspartame, 1 part of magnesium stearate and 1 part of silicon dioxide are added and evenly mixed, and tabletting can be carried out;

(3) and (3) subpackaging the tablets obtained in the step (2).

Example 5

(1) Pulverizing 900 parts of raw materials of eucommia ulmoides and 350 parts of kudzuvine root into coarse powder, adding 8 times of 75% ethanol, performing hot reflux extraction for 2 times, extracting for 2 hours each time, filtering, combining the 2 times of filtrate, concentrating under reduced pressure to obtain an extract with a relative density of 1.2(25 ℃), drying under reduced pressure, pulverizing the dry extract, and sieving with a 80-mesh sieve to obtain an extract;

(2) adding 140 parts of maltodextrin and 140 parts of sodium bicarbonate into the extract obtained in the step (1), uniformly mixing, granulating by using 85% ethanol to prepare a soft material, sieving by using a 20-mesh sieve, and baking at the temperature of less than or equal to 60 ℃. After the alkali granules are prepared, 50 parts of citric acid, 100 parts of tartaric acid, 1.2 parts of sucralose and 1.2 parts of magnesium stearate are added and mixed uniformly, and tabletting can be carried out;

(3) and (3) subpackaging the tablets obtained in the step (2).

The advantages of the product of the invention are verified by the following tests, the test conditions are as follows:

test example 1 ranking test method to assess the likeness of two different products

The order of preference between the effervescent tablet for oral administration prepared in example 3 and the notoginseng tablet (comparative example 1) was evaluated by the rank order test.

The experimental method comprises the following steps: and evaluating the favorite sequence of the two products by adopting a sequencing test method.

Sample preparation and sample presentation: in a sequencing test assessment test, two different samples are presented simultaneously to an evaluator who is asked to indicate the degree of preference for each sample.

Sensory evaluation of the samples: before the appraiser checks, the appraiser rinses the mouth with clean water, spits the water into a container prepared in advance, receives two coded samples, please taste the samples from left to right according to the presentation sequence, rinses the mouth with clean water in the middle, please fill the codes of the samples in the table according to the preference degree from dislike to like.

The evaluation results are shown in table 1.

TABLE 1 taste preference degree table for two products

The results show that: the comparative example was too bitter to swallow. The oral effervescent tablet prepared in example 3 is taken as a liquid, has visual effect due to bubbling, has good taste and is preferred.

Test example 2 order test method for evaluating the degree of convenience of use of two different products

The order of convenience of use of the effervescent tablets for oral administration prepared in example 2 (1 tablet at a time, 3 times a day) and comparative examples 1 (pseudo-ginseng tablet, 2-6 tablets at a time, 3 times a day) and 2 (eucommia ulmoides flat-pressed tablet, 2 tablets at a time, 2-3 times a day) was evaluated by the rank order test.

The experimental method comprises the following steps: the order of convenience of use of the two products was assessed by a sequencing test.

Sample preparation and sample presentation: in a sequencing test assessment test, two different samples are presented simultaneously to an evaluator who is asked to indicate the degree of preference for each sample.

Evaluation of the ease of use of the sample: two samples were distributed to experimenters and handed over to use, example 3 was poured into paper cups, dissolved in hot water, and taken after the water temperature reached. Comparative example the package was torn open and swallowed. Filling the code of the sample into the table according to the convenience degree of taking from inconvenience to convenience.

The evaluation results are shown in table 2.

TABLE 2 two products using convenience degree table

The results show that: comparative examples 1 and 2 were large in tablet size, 6 tablets were taken at a time, and the number of tablets was large, which made swallowing difficult. Example 2 the composition was dissolved in 100ml of water and administered. Example 2 is considered to be the most convenient to use.

Test example 3 comparative method for evaluating the degree of blood lipid reduction and adverse reaction of three different products

Evaluation of effervescent tablet for oral administration prepared in example 1 (1 tablet at a time, 3 times a day), comparative example 1 (pseudo-ginseng tablet, 2-6 tablets at a time, 3 times a day), comparative example 2 (eucommia ulmoides flat-pressed tablet, 2 tablets at a time, 2-3 times a day)

1. 75 patients with treated fatty liver combined hyperlipidemia were selected for study, 25 patients included group A using comparative example 1, 25 patients included group B using comparative example 2, and the remaining 25 patients included group C using example 2. Group a 15 men and 10 women; the age is 42-78 years, and the average age is 61.23 + -3.58 years. Group B15 men and 10 women; the age is 41-76 years, and the average age is 61.42 + -3.61 years. Group C15 men and 10 women; the age is 40-77 years, and the average age (61.30 +/-3.59) is. The comparative analysis of each data among groups shows that the difference has no statistical significance (P is more than 0.05) and is comparable. Inclusion criteria were: meeting the clinical diagnosis standard of fatty liver and hyperlipemia [3 ]; secondly, the diagnosis is confirmed by combining the detection of physical signs, symptoms, pathology and the like; signing an informed consent; approved by the ethical committee of hospitals. Exclusion criteria: combining dysfunction of other organs (such as heart, lung and the like); ② combining malignant tumors; ③ taking the lipid-lowering medicine within 3 months; fourthly, combining immune or infectious diseases; fifthly, merging the pregnancy or lactation period.

2. The treatment method comprises the following steps: group a was treated with comparative example 1 alone. Group B was treated with comparative example 2 alone. Group C was treated with example 2. The 3 groups all adopt conventional hypoglycemic drugs: metformin is taken orally, 0.25 g/time and 3 times/d; acarbose was administered orally at 50 mg/dose, 3 times/day. Meanwhile, in the process of reducing blood sugar, intervention such as diet, exercise, work and rest is given. 1 week is 1 course in 3 groups, and 4 courses of treatment are given.

3. Observation indexes are as follows: the blood lipid, blood glucose and inflammatory factor levels before and after treatment were compared in both groups. The blood lipid index includes Triglyceride (TG), low density lipoprotein (LDL-C), high density lipoprotein (HDL-C) and Total Cholesterol (TC), the blood glucose index includes fasting blood glucose (FPG), postprandial 2h blood glucose (2hPG), and the inflammatory factor includes C Reactive Protein (CRP) and interleukin 6 (IL-6). Collecting a specimen: in the early morning under an empty stomach state, 5mL of elbow venous blood is extracted, anticoagulated, centrifuged and then timely inspected.

4. The statistical method comprises the following steps: processing by SPSS18.0 software, and performing X2 test on the counting data, wherein the counting data is represented by [ n (%) ]; the measured data is subjected to t test and expressed by (x + -s). P < 0.05 indicates that the difference is statistically significant.

5. Test results

5.1, comparison of blood lipid index levels of each group: in the aspect of blood lipid index levels such as TC, TG, HDL-C, LDL-C and the like, the differences of 3 groups before treatment have no statistical significance (P is more than 0.05); after treatment, all the groups 3 were improved compared to before treatment, with TC, TG, and LDL-C lower than those in groups A and B, and HDL-C higher than those in groups A and B, and the differences were statistically significant (P < 0.05), as shown in Table 3.

TABLE 3 comparison of the blood lipid indices (x. + -. s, mmol/L) for each group

Note: p < 0.05 for comparison before and after treatment; delta indicates that P < 0.05 in group C after treatment compared to groups A and B.

5.2 comparing blood glucose and inflammatory factors in each group: the differences were not statistically significant (P > 0.05) in the FPG, 2hPG and CRP, IL-6 levels, compared to the pre-treatment group 3; the post-treatment levels were lower in all 3 groups compared to pre-treatment, while the differences were statistically significant (P < 0.05) in group C compared to groups A and B, as shown in Table 4.

TABLE 4 comparison of blood glucose and inflammatory factors (x. + -.s) for each group

Note: p < 0.05 for comparison before and after treatment; delta indicates that P < 0.05 in group C after treatment compared to groups A and B.

5.3 Collection of various adverse reactions

The long-term use of notoginseng may cause dry mouth, dry tongue, emotional restlessness, insomnia, and other symptoms, and some patients may suffer nausea and vomiting. The eucommia bark is easy to cause digestive system reactions such as nausea, vomiting, abdominal pain, abdominal distension and diarrhea after being taken for a long time. A. The adverse reactions after B, C groups were treated for 4 courses were as follows.

TABLE 5

Group of	Dry mouth and restless tongue	The feeling of emotions is uneasy,	insomnia	Nausea and vomiting	Abdominal pain, abdominal distension and diarrhea
						Group A n 25	20	5	10	5	1
Group B n 25	0	0	0	10	10
						Group C, n is 25	0	0	0	0	0

The group A of the comparative example 1 is taken, and the conditions of dry mouth, dysphoria and insomnia caused by the pseudo-ginseng are obvious. Group B of comparative example 2 had a significant digestive response induced by eucommia bark. In the group C of the embodiment 2, the pseudo-ginseng and the eucommia ulmoides are used as main medicines, and the adverse reactions of thirsty, tongue dysphoria, insomnia, digestive system reaction and the like caused by the pseudo-ginseng and the eucommia ulmoides are obviously improved after the pseudo-ginseng and the eucommia ulmoides are matched with the efficacies of thirst due to kudzuvine root fever and diabetes due to yin deficiency and the efficacies of regulating intestinal tracts and clearing heat toxin in vivo of the yacon. The compatibility of the medicines of the embodiment 2 is obviously superior to that of a single pseudo-ginseng or eucommia product.

5.4 conclusion: the blood fat reducing effect of the group C after treatment is better than that of the group A and the group B (P is less than 0.05), which fully indicates that the blood fat reducing effect of the group C is better than that of single panax notoginseng or eucommia ulmoides, and the combined medication embodies the value of the medicines after compatibility. In addition, in the aspect of inflammatory factor indexes, the level of the group C is lower than that of the group A and the group B (P is less than 0.05), which shows that the effect of inhibiting inflammatory reaction of the compatible medicament of the example 1 is better than that of single pseudo-ginseng or eucommia bark, CRP and IL-6 are markers of inflammatory reaction of organisms, and the lipid-lowering medicament can achieve the purpose of reducing the level of inflammatory factors by reducing the blood fat level, relieving the degree of fatty liver, reducing stimulation and damage to blood vessel walls and inhibiting the over-expression of inflammatory reaction.

In conclusion, the clinical treatment of the embodiment 1 has an obvious effect of reducing blood fat compared with that of singly using the pseudo-ginseng tablets or the eucommia ulmoides flat tablets, and has better effects of reducing blood fat, reducing blood sugar and inhibiting over-expression of inflammatory mediators, low adverse reaction and higher popularization value.

Because the raw materials of pseudo-ginseng and eucommia bark preparations such as pseudo-ginseng and eucommia bark are bitter, the compliance of patients is poor, and the tablets are large, the number of tablets taken at one time is large, and the tablets are difficult to swallow for old patients, the oral effervescent tablet has the advantages of good taste, novelty and convenient taking compared with the comparative example.

Finally, it is noted that the above-mentioned preferred embodiments illustrate rather than limit the invention, and that, although the invention has been described in detail with reference to the above-mentioned preferred embodiments, it will be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the scope of the invention as defined by the appended claims.